Supporting Information for

Synthesis of an NO-releasing Prodrug of Rofecoxib

F. Conrad Engelhardt,* Yao-Jun Shi, Cameron J. Cowden, David A. Conlon, Brenda Pipik,
George Zhou, James M. McNamara, Ulf-H. Dolling

Department of Process Research, Merck & Co., Inc, PO Box 2000, Rahway, NJ 07065-0900
conrad_engelhardt@merck.com

General Methods: Solvents were used directly from the commercial supplier with no additional drying or purification. FT-IR spectra are reported in cm^{-1} , ^1H and ^{13}C NMR spectra were obtained in CDCl_3 solutions at 400 MHz (for ^1H) and 75 MHz (for ^{13}C), respectively. Chemical shifts are reported in delta (δ units), parts per million (ppm) relative to the singlet at 7.26 ppm of CDCl_3 for ^1H and in ppm relative to the center line of the triplet at 77 ppm of CDCl_3 for ^{13}C .

Copies of ^1H and ^{13}C Spectra and IR for compounds (page number)

Compound	^1H	^{13}C	IR
12a	S2	S3	S4
13	S5	S6	---
27	S7	S8	S9
1	S10	S11	S12
2	S13	S14	S15
3	S16	S17	S18

nmr400b h-1 decoupled c-13

68.66

76.91
77.23
77.55

126.89
127.62
127.89
128.25
129.43
129.46
135.26
136.65
138.08
140.97

15.1

70.5
77.6
77.2
76.9

130.6
129.5
129.0
128.9
127.9
127.0
125.9
125.6

143.0

155.6

172.7

73073-147-2_c-13 nmr400c

26.3
26.7
29.5
29.3
20.8

44.4

64.7
65.5

77.5
77.2
76.9
73.3

143.7
139.6
139.4
137.5
135.2
130.4
129.5
128.3
126.2
127.2

170.5
166.0

77.5
77.2
76.9

44.5

64.9

77.5
77.2
76.9

143.5
142.3
139.7
136.2
134.3
130.3
129.8
128.5
127.2

171.0
172.2

15.4
20.8

65.3

77.5
77.2
76.9

143.6
138.8
136.3
134.4
133.9
130.0
129.8
128.3
127.9
125.7

173.5
171.2